Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA -1.37%19 Receivables Turnover is 2.90 as of Jun. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 948 Drug Manufacturers companies, Corona Remedies ranks better than 78.48% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Corona Remedies's Revenue for the
three
months ended in Jun. 2026 was ₹4,224 Mil. Corona Remedies's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹1,456 Mil.
Hence, Corona Remedies's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.90.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Corona Remedies Receivables Turnover Related Terms
Corona Remedies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a Receivables Turnover of 2.90 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Corona Remedies and its competitors. According to the industry distribution chart, Corona Remedies ranks #204 out of 948 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is Corona Remedies' Receivables Turnover too high?
Corona Remedies' current Receivables Turnover is 2.90. The Drug Manufacturers industry median Receivables Turnover is 5.08. Corona Remedies' value of 2.90 is 42.9% below this industry median. Based on the distribution chart, Corona Remedies ranks #204 out of 948 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #204 out of 948 companies for Receivables Turnover. This places Corona Remedies in the top 22% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.08. Corona Remedies' value of 2.90 is 42.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Receivables Turnover of 2.90 is 42.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Receivables Turnover is 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Receivables Turnover of 2.90. The current Receivables Turnover is 2.90 and 42.9% below the Drug Manufacturers industry median of 5.08. Corona Remedies' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Receivables Turnover is 2.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
19GF Score
Get the complete analysis for NSE:CORONA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
